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Ethanol is metabolized into acetaldehyde mainly by the action of alcohol dehydrogenase
in the liver, while mainly by the action of catalase in the brain. Aldehyde dehydrogenase-2
metabolizes acetaldehyde into acetate in both organs. Gene specific modifications
reviewed here show that an increased liver generation of acetaldehyde (by transduction
of a gene coding for a high-activity liver alcohol dehydrogenase ADH1∗B2) leads
to increased blood acetaldehyde levels and aversion to ethanol in animals. Similarly
aversive is an increased acetaldehyde level resulting from the inhibition of liver aldehyde
dehydrogenase-2 (ALDH2) synthesis (by an antisense coding gene against aldh2 mRNA).
The situation is diametrically different when acetaldehyde is generated in the brain.
When the brain ventral tegmental area (VTA) is endowed with an increased ability to
generate acetaldehyde (by transfection of liver rADH) the reinforcing effects of ethanol
are increased, while a highly specific inhibition of catalase synthesis (by transduction of a
shRNA anti catalase mRNA) virtually abolishes the reinforcing effects of ethanol as seen by
a complete abolition of ethanol intake in rats bred for generations as high ethanol drinkers.
Data shows two divergent effects of increases in acetaldehyde generation: aversive in the
periphery but reinforcing in the brain.
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INTRODUCTION: THE ETHANOL MOLECULE
Ethanol became part of our ecology over 200 million years ago
when yeast started fermenting carbohydrates in fruits and grains,
generating ethanol (Ratcliff et al., 2012). Animals were subse-
quently exposed to ethanol in these naturally fermented products.
It has been proposed (Duddley, 2000; Dominy et al., 2004) that
animals that perceived ethanol as a pleasant substance had an evo-
lutionary advantage since they also increased the intake of calories
from these sources.
The pleasant effects of alcohol explain why humans engaged in
manufacturing it. The book of Anni, in 1700 BC Egypt describes
an overt intoxication and the rules of proper behavior to be fol-
lowed in a beer shop. Subsequently, its distillation is described
in 900 AD and its production and massive consumption were
brought by the Industrial Revolution (Hogarth, 1751). While in
moderate doses alcohol generates motivational and reinforcing
effects, in high doses it can generate aversion, inducing cognitive
deficits, motor incoordination and emesis.
There is general agreement that in high concentrations ethanol
modifies some neurotransmitter receptors by allosteric bind-
ing to their hydrophobic pockets, for example on the gamma-
amino butyric acid receptor (GABA-A) (Harris and Allan,
1985; Suzdak et al., 1986; Huidobro-Toro et al., 1987). These
hydrophobic pockets are also modifiable, with similar effects,
by barbiturates and anesthetics, such as enfluorane, isofluorane
and other long chain aliphatic alcohols (Levitan et al., 1988;
Pritchett et al., 1989; Mihic et al., 1994, 1997; Krasowski et al.,
1998).
Another receptor upon which ethanol generates hyp-
notic/anesthetic effects is the N-Methyl-D-Aspartate (NMDA)
glutamate receptor (Lovinger et al., 1989; Weight et al., 1992).
Ethanol binds allosterically to the NMDA receptor (Wright et al.,
1996; Wirkner et al., 1999), an effect that leads to the interruption
of cognitive processes, consolidation of memory and anesthesia
(Robbins and Murphy, 2006). The hydrophobic pockets in the
NMDA receptor can also be modified by anesthetics of diverse
structures such as halothane, cyclopropane and xenon (Ogata
et al., 2006). However, several studies indicate that the hypnotic
and anesthetic effects of ethanol do not correlate with its reward-
ing properties (Riley et al., 1977; Daoust et al., 1987; Elmer et al.,
1990).
ACETALDEHYDE AS A MEDIATOR OF THE EFFECTS OF
ETHANOL
Crabbe et al. (2006) reviewed the literature on the putative role of
93 genes likely involved in the effects of ethanol. Those involved
with greater frequency were alcohol dehydrogenase and aldehyde
dehydrogenase. The present review deals primarily with stud-
ies that show the effects generated by increasing or reducing
acetaldehyde levels and/or the ability of the liver and brain to
generate it. The studies were conducted in Wistar-derived rats
selectively bred for over 80 generations, which led to two lines of
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rats: the UChA (abstainer) and the UChB (bibulous). The stud-
ies to be presented dovetail with many other studies described
in this issue and potentiate the concept that acetaldehyde is a
major contributor of the effects of ethanol, both aversive and
rewarding.
Ethanol (CH3-CH2OH) is a small and relatively non-reactive
molecule, thus requiring high concentrations to generate its
effects. In high concentrations ethanol mainly interacts with
hydrophobic pockets in proteins. On the other hand, acetalde-
hyde (CH3-CHO) is able to bind to amines (e.g., lysine residues)
in proteins, generating Schiff bases (CH3-C=N-CH2-R), also
binding to dopamine generating salsolinol, which has also been
studied as a mediator of ethanol effects. Recently, Juricic et al.
(2012) confirmed early studies by King et al. (1974) showing that
acetaldehyde can, in addition to generating salsolinol, condense
non-enzymatically with a carbon vicinal to a hydroxyl group in
dopamine, yielding isosalsolinol (Figure 1). It was shown that
commercial salsolinol (Sigma-Aldrich, sold prior to 2012) used
in this field[,] is a mixture of four dopamine-acetaldehyde con-
densation products: (R)- and (S)- salsolinol (85%) and (R)- and
(S)- isosalsolinol (10–15%).
AVERSIVE EFFECTS OF LIVER-GENERATED ACETALDEHYDE
Among the first studies that described powerful effects of
acetaldehyde were those seen in East Asians when consuming
ethanol. Studies in the 80’s demonstrated that 20–40% of individ-
uals of East Asian origin (e.g., Japan, China, Korea) develop dys-
phoric effects when consuming alcohol; the effects often include
peripheral vasodilatation and overt facial flushing, tachycardia,
headache, nausea and emesis (Mizoi et al., 1983). Such individuals
carry a point mutation in the gene that codes for the high affinity
(low Km) mitochondrial aldehyde dehydrogenase-2 (ALDH2∗2),
a mutation that greatly reduces its affinity for NAD+, thus
generating a virtually inactive dehydrogenase. Subjects carrying
the ALDH2∗2 polymorphism develop large increases in blood
acetaldehyde (reaching 80–100µM; over 5-fold that of subjects
who carry the wild-type enzyme: ALDH2∗1). It is important to
FIGURE 1 | Acetaldehyde condensation with dopamine. Products
formed in the non-enzymatic condensation are (R)- and (S)-salsolinol and
(R)- and (S)- isosalsolinol (from Juricic et al., 2012).
note that these increases are due not only to the inability of liver to
oxidize acetaldehyde into acetate, but also the inability of periph-
eral tissues and vascular tissues to oxidize acetaldehyde; tissues
which also express the gene for high affinity mitochondrial alde-
hyde dehydrogenase. In venous blood of individuals carrying the
normal ALDH2∗1 enzyme, the levels of acetaldehyde are virtually
nil; while levels of the order of 15–20µM are found when arterial
blood is sampled (see Quintanilla et al., 2007). The marked abil-
ity of endothelial tissues to metabolize acetaldehyde is of major
importance in understanding why a lipophilic metabolite such
as acetaldehyde does not cross the tight-junction cells that con-
stitute the blood brain barrier (vide infra), and why the effects
of acetaldehyde are so different in the periphery vs. the central
nervous system.
A number of studies have shown that individuals car-
rying the ALDH2∗2 allele are protected between 66%
(heterozygous ALDH2∗1/ALDH2∗2) and 99% (homozy-
gous ALDH2∗2/ALDH2∗2) against alcoholism (Harada et al.,
1982; Thomasson et al., 1991; Higuchi, 1994; Tu and Israel, 1995;
Chen et al., 1999; Luczak et al., 2006; Zintzaras et al., 2006).
Hence, disulfiram (Antabuse®), a drug that non-specifically
inhibits ALDH2, is the most efficient drug in the treatment of
alcoholism provided its daily intake is secured by another person
Chick et al. (1992), see meta-analysis by Jørgensen et al. (2011).
Recent studies in animals (Escrig et al., 2012) show that disul-
firam, while not showing behavioral effects on its own, reverses
the anxiolytic effects of ethanol or shows anxiogenic effects. The
administration of a large dose of acetaldehyde (100mg/Kg) being
anxiogenic per se.
Animal studies also support the concept that alcohol is a
prodrug vis-a vis their aversive effects. Rats of the UChA line
(virtually Abstainer) display a mutation in the aldh2 gene (Sapag
et al., 2003; see Quintanilla et al., 2006), which codes for an
enzyme with a higher Km for NAD+ and a lower Vmax that the
ALDH2 of heavy drinker animals (UChB; Bibulous). Further, the
levels of arterial acetaldehyde display a large “acetaldehyde burst,”
reaching 40–50µM (vs. 10–20µM for controls), which deters
their alcohol intake (Quintanilla et al., 2005b). The mutation in
the ALDH2 gene accounts for 50–60% of the low ethanol intake
of UChA rats (Quintanilla et al., 2005a).
Additional evidence that systemic acetaldehyde is aversive was
seen in gene modification studies that inhibited ALDH2 activity
and elevated blood acetaldehyde levels. In studies by Ocaranza
et al. (2008), UChB (drinker) rats were allowed access to 10%
ethanol and water for 60 days (intakes of 7–8 g ethanol/kg/day),
and were deprived of ethanol for 3 days. At the time of depri-
vation animals were injected an adenoviral vector (preferential
liver tropism, but no crossing of blood-brain barrier) coding for
an antisense RNA against ALDH2 mRNA, which lowered liver
ALDH2 activity by 80–90% (p < 0.001). When ethanol access
was re-allowed, control (empty virus) animals ingested 1.2 g
ethanol/kg/60min (10-fold higher than a naïve UChB) while ani-
mals treated with the anti ALDH2 antisense ingested 0.5–0.6 g
ethanol/kg/60min (p < 0.005). This inhibitory effect remained
constant for the 34 days of the study. Acetaldehyde levels of
animals that received the antisense against ALDH2 were of the
order of 60 vs. 15–20µM in controls.
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In another study (Rivera-Meza et al., 2010), alcohol intake by
UChB rats was reduced by 50% by the transfer into the liver (via
an adenoviral vector) a rat homolog of the fast human alcohol
dehydrogenase ADH1B∗2 (ADH-47His) which elevated 6-fold
liver ADH activity. In these studies, arterial acetaldehyde levels
in the ADH1B∗2 transduced animals increased from 20 to 80µM
after the i.p administration of 1.0 g ethanol/kg. These studies, in
addition to confirming that increases in acetaldehyde at physiolog-
ical levels generate alcohol aversion in the animals, explain a large
number of studies showing that humans carrying the ADH1B∗2
(ADH-47His) gene are protected against alcoholism (see meta-
analysis by Zintzaras et al., 2006). The lack of understanding of
why this enzyme protected against alcoholism stems from the fact
that acetaldehyde in humans carrying the ADH1B∗2 was deter-
mined in venous blood; being close to zero. As indicated earlier,
venous blood, after having perfused the rich ALDH2∗1 peripheral
tissues are devoid of acetaldehyde.
From the above, genetic and pharmacokinetic evidence indi-
cates that blood acetaldehyde in concentrations of 40–80µM is
aversive to animals and to humans. The mechanism by which
ethanol generates vasodilatation, hypotension and nausea could
be the release of histamine from mast cells (Shimoda et al.,
1996). However, antihistaminic drugs do not increase the intake
of ethanol in low drinker UChA rats (Quintanilla and Tampier,
unpublished). We would like to point out that it is not clear if
the aversive effects of acetaldehyde are generated in the periphery
beyond the liver or actually start in nerves terminals that travel
from the liver to the CNS, a matter that requires study.
BRAIN ACETALDEHYDE AS A MEDIATOR OF THE
REWARDING EFFECTS OF ETHANOL
Alcohol is absorbed from the stomach and intestine and is
distributed throughout the body, reaching identical concentra-
tions in the water of all tissues, including the brain. Ethanol
is metabolized mainly in the liver by alcohol dehydrogenase
(Km = 2mM) generating acetaldehyde, which is further oxi-
dized to acetate by a ubiquitous high affinity aldehyde
dehydrogenase (Km < 0.2µM). Other enzymes that oxidize
ethanol into acetaldehyde are catalase and cytochrome p4502E1
(Figure 2). These latter enzymes play a minor role in metab-
olizing ethanol in the liver (Mezey, 1976; Khanna and Israel,
1980).
An important question in this field is whether liver-generated
systemic acetaldehyde (normally not exceeding 20µM in arte-
rial blood after ethanol intake) can cross the blood brain barrier.
Studies indicate that since the capillaries of the blood brain
barrier have tight junctions (rather than open pores) acetalde-
hyde must first enter the ALDH2-rich endothelial cells of the
barrier, which clear the acetaldehyde. Thus, under normal con-
ditions of ethanol metabolism, systemic acetaldehyde does not
cross the blood brain barrier (Eriksson, 1977; Lindros and
Hillbom, 1979; Peterson and Tabakoff, 1979; Stowell et al., 1980).
Only when systemic concentrations exceed 100µM, following
the administration of systemic acetaldehyde, acetaldehyde enters
the CNS (Tabakoff et al., 1976). High concentrations of brain
acetaldehyde can also be attained by the systemic (i.p. or s.c.)
administration high doses of acetaldehyde.
FIGURE 2 | Metabolismof ethanol into acetaldehydeby three enzymatic
systems. In the liver alcohol dehydrogenase (ADH) plays a major role, while
catalase and cytochrome P450 (CYP2E1) play minor roles. In the brain, ADH
(ADH1) is not expressed, but catalase mainly, and CYP2E1 to a minor
extent, metabolize ethanol into acetaldehyde. Aldehyde dehydrogenase-2
(ALDH2) is present in virtually all cells (Drawn from Zimatkin et al., 2006).
Alcohol dehydrogenase is not expressed in the brain (see
Zimatkin et al., 2006; Deitrich, 2011), however, acetaldehyde can
be generated from ethanol by the catalase reaction, and to aminor
extent by CYP2E1, both enzymes present in brain (Tampier and
Mardones, 1979; Aragon et al., 1992; Gill et al., 1992; Zimatkin
et al., 2006). In vitro studies indicate that catalase generates 60–
70% of brain acetaldehyde while CYP2E1 some 20% (Zimatkin
et al., 2006). In vivo studies by Zimatkin and Buben (2007)
showed that ethanol infusion into the cerebral ventricles can
generate acetaldehyde (achieving 60µM), as detected in the cere-
brospinal fluid. However, the concentrations of ethanol infused
(85–90mM) were in the anesthetic range (legal limits in most
countries are 6–17mM). In these studies, the catalase inhibitor
aminotriazole reduced acetaldehyde levels in the cisterna magna.
While such studies were promising in pointing out a major
effect of catalase in acetaldehyde generation, the low specificity
of aminotriazole required caution.
The question remains as to whether enough acetaldehyde is
generated following amoderate ethanol intake to induce pharma-
cological effects. Studies in which aminotriazole was administered
showed a reduction in voluntary ethanol intake by rats (Aragon
and Amit, 1992; Tampier et al., 1995). However, aminotriazole
also inhibited the consumption of food and of saccharine solu-
tions (Rotzinger et al., 1994; Tampier et al., 1995), indicating
non-specific actions. With a more direct approach, Ledesma and
Aragon (2013) showed that reducing brain hydrogen peroxide
levels (required by catalase to oxidize ethanol to acetaldehyde)
reduced alcohol-induced conditioned place preference. Most
early studies in the field have been conducted by either admin-
istering large doses of acetaldehyde or by the use of inhibitors or
inducers of catalase. The reader is referred to recent reviews in this
field (Quertemont et al., 2005; Deitrich, 2011; Correa et al., 2012).
Overall, the field generally agrees with the view that acetalde-
hyde mediates the reinforcing effects of ethanol; however, the
methodologies used to achieve such consensus are varied, in some
cases employing non-physiological concentrations and routes
of administration of ethanol or acetaldehyde or non-specific
inhibitors.
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FIGURE 3 | Virtual long-lasting abolition of ethanol intake following
the single administration of an anticatalase viral vector into the brain
ventral tegmental area (VTA). (A) Ethanol drinker rats (UChB line) were
microinjected into the VTA 1.0 microliter (8 × 104 particles) of a lentiviral
vector coding for an shRNA against catalase mRNA. Controls received the
empty lentiviral vector. Four days after the vector injection animals had 24-h
access to 10% ethanol and water. (B) Animal weight was not affected by
the anticatalase vector. Water intake (not shown) was not modified either
(from Karahanian et al., 2011). Replicate studies by Quintanilla et al. (2012)
showed that the anticatalase lentiviral vector reduced VTA catalase activity
by 70–80%.
Early studies showed that rats self-administer acetaldehyde
intracerebrally (Amit et al., 1977; Brown et al., 1979; Amit and
Smith, 1985), indicating a reinforcing effect of this metabolite
at the central nervous system level. Rodd et al. (2005) demon-
strated that rats selectively bred as alcohol drinkers (strain P
of Indianapolis) self-administer both ethanol and acetaldehyde
into the brain ventral tegmental area (VTA). Acetaldehyde (6 ×
10−6 M) showed reinforcing effects at concentrations that were
1000 smaller than those required for ethanol (17 × 10−3 M) self-
administration. The question remained as to whether enough
acetaldehyde is generated in the brain to develop rewarding and
reinforcing effects when ethanol is consumed orally.
Recently, a specific gene blocking technique allowed inhibit-
ing brain catalase synthesis. Karahanian et al. (2011) developed
lentiviral vectors coding a shRNAdesigned to inhibit the synthesis
of catalase. Lentiviral vectors permanently integrate into the cell
genome the genes they carry. A single stereotaxic administration
of an anti-catalase lentiviral vector (anticatalase-lenti) into the
VTA, which reduced catalase levels by 70–80% (Quintanilla et al.,
FIGURE 4 | Dopamine levels in the nucleus accumbens following
acute ethanol administration. Effect of anticatalase vector
administration into the ventral tegmental area on dopamine release
monitored in the ipsilateral nucleus accumbens. (A) Inhibition by
anticatalase-lentiviral vector of dopamine efflux into the microdialysis fluid
of nucleus accumbens (shell) induced by the systemic administration of
ethanol (1 g/kg i.p.). (B) Anticatalase-lentiviral vector does not affect
dopamine efflux into the microdialysis fluid of nucleus accumbens (shell)
induced by d-amphetamine (0.1mM) or (C) Anticatalase-lentiviral vector
does not affect dopamine efflux into the microdialysis fluid of nucleus
accumbens (shell) induced by KCl (100mM) added to the microdialysis
fluid. (From Karahanian et al., 2011).
2012), virtually abolished the voluntary ethanol consumption
(up to 95%) by drinker UChB rats for 40–50 days (Karahanian
et al., Figure 3). The lentiviral anticatalase shRNA administra-
tion also abolished the increased release of dopamine in nucleus
accumbens induced by ethanol administration (Figure 4). It is
noteworthy that rats were not unduly affected (water intake,
body weight, behavior) by the administration of the anticatalase
lentiviral vector (Karahanian et al., 2011), as in the brain enzymes
other than catalase are mainly responsible for the elimination
of hydrogen peroxide (Halliwell, 2006), namely glutathione per-
oxidases and most active peroxiredoxins (Turrens, 2003; Rhee
et al., 2005). Overall, the rewarding effects of ethanol appear to be
mediated by acetaldehyde generated in the brain by the action of
catalase. One can hypothesize that an increased ability of VTA to
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FIGURE 5 | Administration of the alcohol dehydrogenase coding gene
(rat liver adh) into the VTA increases voluntary alcohol intake in rats
(UChB) bred as alcohol drinkers. (A) Four days after the injection of the
lentiviral vectors, animals were allowed free availability of 5% (v/v) ethanol
and water. Rats significantly (p < 0.001) increased their alcohol intake when
injected with a lentiviral vector encoding alcohol dehydrogenase (rADH)
(Lenti-ADH) into the ventral tegmental area compared to that observed
after treatment with an empty lentiviral vector (control-Lenti) (A). (B) No
differences in body weight were observed along the experiment in
Lenti-ADH-treated rats vs. control-Lenti virus-treated rats. Abscissa: days of
ethanol availability. (From Karahanian et al., 2011).
generate acetaldehyde, induced by genetic modification, should
also demonstrate an increased rewarding effect of ethanol. This
was tested by the administration into the VTA of a lentiviral
vector coding for liver alcohol dehydrogenase. In these studies,
to avoid a ceiling of the rewarding effect of acetaldehyde gener-
ated by catalase (when 10% ethanol is available to the animals,
ethanol intake approaches the rate of whole body degradation),
animals were allowed access to 5% ethanol and water. As can
be seen in Figure 5, animals transduced with the liver alcohol
dehydrogenase (ADH) into the VTA significantly increased their
ethanol intake compared to that of animals administered the con-
trol vector. The animals administered the vector coding liver ADH
or the control vector did not show differences in body weight
or behavior.
BRAIN ACETALDEHYDE AS A MEDIATOR OF THE ALCOHOL
DEPRIVATION EFFECT (ADE)
Sinclair and Senter (1968, 1977) showed that chronic intake of
ethanol by rats, followed by a period of alcohol deprivation and
FIGURE 6 | Increased ethanol intake by UChB rats chronically exposed
to ethanol, subsequently deprived and ethanol re-exposed.Marked
inhibition of intake following the administration of an anticatalase lentiviral
vector. Animals with ad-libitum access to 10 and 20% ethanol and water for
60 days. Baseline data correspond to the average of ethanol intake
restricted to only 1h a day, for 7 days immediately prior to alcohol
deprivation. A single intra-ventral tegmental area injection of an
anticatalase-lentiviral vector inhibited the first 1-h ethanol intake after the
first and second ethanol deprivation (ADE) periods of 15 days.
The total height of each bar represents the sum of ethanol intake
(g ethanol/kg/60min) of the 10% solution (empty bars) plus that of the 20%
solution (gray bars). The -/ /- symbol in the x-axis represents the 15-day
deprivation period. (A) Control viral vector. (B) Anticatalase viral vector.
Arrows indicate the administration of either control lentiviral vector or
anticatalase-lentiviral vector prior to the 15 days of deprivation. The first and
second re-exposure consumptions were significantly different from
baseline. The inhibition induced by anticatalase vector administration was
67% (p < 0.001) after the first deprivation period, and 80% (p < 0.001) after
the second deprivation period. Note also the marked increases in ethanol
binge-drinking induced in control vector treated animals after the first and
second ethanol intake and deprivation cycles (From Tampier et al., 2013).
subsequent re-exposure to ethanol leads animals to a marked
increase of their ethanol intake above their basal pre-deprivation
levels. This effect, termed the “alcohol deprivation effect” (ADE),
is shown by a marked increase in voluntary intake of ethanol
solutions (akin to binge-drinking) over baseline drinking when
ethanol is reinstated after the period of alcohol deprivation
(Spanagel and Hölter, 1999; Rodd-Henricks et al., 2001). An ADE
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can be observed after a short (1–3 days; Sinclair and Li, 1989;
Agabio et al., 2000) or a long (up to 60–75 days) deprivation
period (Sinclair et al., 1973; Spanagel and Hölter, 1999), but is
not observed in non-deprived continuously alcohol-treated ani-
mals, suggesting that chronic exposure to ethanol alone is not
sufficient to produce such a marked increase in ethanol intake
(Spanagel and Hölter, 1999). Examination of the ADE phe-
nomenon has revealed that at least 3–4 weeks of a continuous
alcohol-drinking experience are required before deprivation to
elicit an ADE (Spanagel and Hölter, 1999).
A number of studies showed that repeated alcohol intake–
deprivation–re-administration episodes increase the expression
of ADE (see Rodd et al., 2008) and Vengeliene and colleagues
(2009) have shown that the motivational and reinforcing effects
of ethanol are increased in the ADE condition, as animals experi-
encing the ADE will increase their work to procure ethanol.
Tampier et al. (2013) asked whether in the ADE condition a
greater reinforcing effect of ethanol, leading to binge drinking, is
also mediated by acetaldehyde (thus, also by products generated
from acetaldehyde). It was postulated that if increases in ethanol
intake induced by ADE were mediated by acetaldehyde, inhibi-
tion of VTA catalase synthesis bymicroinjection of an anticatalase
lentiviral vector should inhibit ADE binge-drinking. To test this
question rats were allowed for 60 days 24-h access to 10 and 20%
ethanol solutions and water. On day 61, rats were divided into 2
groups matched for similar 24-h alcohol consumption and pref-
erence. One group received an intracerebral administration of
the control lentiviral vector and was immediately deprived for
15 consecutive days of both the 10 and 20% ethanol solution,
while water was the sole fluid available. The second group was
injected into the VTA the anticatalase-Lenti-shRNA. As for the
viral control group, these rats were returned to their home cage
and deprived for 15 days of both 10 and 20% ethanol solutions.
Following the 15 days of ethanol deprivation, re-exposure to free-
choice intake of 10 and 20% ethanol and water started at 1 PM
(on a normal daily cycle) and lasted for 7 days. Alcohol intake was
recorded in all groups on the first hour of re-exposure (also for
24 h after alcohol re-exposure each day for 7 days; data not shown
see Tampier et al., 2013). Thereafter, rats received a second period
of 15 days of ethanol deprivation and further 7 days of ethanol
drinking; again ethanol intake on the first hour of re-intake was
recorded. Figure 6 indicates that (1) UChB rats reproduced the
ADE binge drinking condition showing large amounts of ethanol
consumed on the first hour post ethanol deprivation (achieving
an intoxicating 2 g/kg/60min) (2) subsequent deprivation ADE
cycles increased ethanol intake with a greater consumption of the
more concentrated ethanol solution (in line with a more reinforc-
ing effect of ethanol after ADE), and (3) the increased in ethanol
intake in the ADE condition was strongly inhibited by the anti-
catalase vector. After the second deprivation cycle ethanol intake
was inhibited by 80%. The above study strongly suggests possible
therapeutic avenues in the treatment of alcoholism. It should be
noted that administration of viral vectors is used in human thera-
pies (Kaplitt et al., 2007) and are approved by agencies such as the
U.S. Food and Drug Administration (FDA). Additional studies
are being conducted (Karahanian et al. under review) to deter-
mine if an overexpression of rat ALDH2 in the VTA also inhibits
the ADE-induced increases in ethanol intake.
CONCLUSIONS
Gene-based specific modifications show that an increased liver
generation of acetaldehyde, leading to increased blood acetalde-
hyde levels, results in aversion to ethanol in animals. Similarly,
aversion to ethanol results from an increased acetaldehyde level
resulting from the inhibition of liver aldehyde dehydrogenase-2
synthesis. The situation is radically different when acetaldehyde
is generated in the brain. When the brain ventral tegmental area
is endowed with an increased ability to generate acetaldehyde the
reinforcing effects of ethanol are increased, while a highly specific
inhibition of catalase synthesis virtually abolishes the reinforc-
ing effects of ethanol as seen by a complete abolition of ethanol
intake. Data show two divergent effects of increases in acetaldehyde
generation: aversive in the periphery but reinforcing in the brain.
ACKNOWLEDGMENTS
The authors’ studies reported were supported by FONDECYT
grants # 1095021; #1130012, #1120079 and #1110263 and
the Millennium Scientific Initiative P09-015-F. Dr. Mario
Rivera-Meza received a FONDECYT postdoctoral fellowship
(#3110107).
REFERENCES
Agabio, R., Carais, M. A. M., Lobina,
C., Pani, M., Reai, R., Vacca, G.,
et al. (2000). Development of short-
lasting alcohol deprivation effect
in Sardinian alcohol-preferring
rat. Alcohol 21, 59–62. doi:
10.1016/S0741-8329(00)00072-0
Amit, Z., Brown, Z. W., and Rockman,
G. E. (1977). Possible involvement
of acetaldehyde, norepinephrine
and their tetrahydroisoquinoline
derivatives in the regulation of
ethanol seld-administration. Drug.
Alcohol Depend. 2, 495–500. doi:
10.1016/0376-8716(77)90049-7
Amit, Z., and Smith, B. R. (1985). A
multi-dimensional examination of
the positive reinforcing properties
of acetaldehyde. Alcohol 2,
367–370. doi: 10.1016/0741-8329
(85)90077-1
Aragon, C. M., and Amit, Z. (1992).
The effect of 3-amino-1 2, 4-
triazole on voluntary ethanol con-
sumption: evidence for brain cata-
lase involvement in the mechanism
of action. Neuropharmacology 31,
709–712. doi: 10.1016/0028-3908
(92)90150-N
Aragon, C. M., Rogan, F., and Amit,
Z. (1992). Ethanol metabolism
in rat brain homogenates by a
catalase-H2O2 system. Biochem.
Pharmacol. 44, 93–98. doi:
10.1016/0006-2952(92)90042-H
Brown, Z. W., Amit, Z., and Rockman,
G. E. (1979). Intraventricular
self-administration of acetaldehyde,
but not ethanol, in naive labo-
ratory rats. Psychopharmacology
64, 271–276. doi: 10.1007/
BF00427509
Chen, Y. C., Lu, R. B., Peng, G. S.,
Wang, M. F., Wang, H. K., Ko, H. C.,
et al. (1999). Alcohol metabolism
and cardiovascular response in
an alcoholic patient homozygous
for the ALDH2*2 variant gene
allele. Alcohol. Clin. Exp. Res 23,
1853–1860. doi: 10.1111/j.1530-
0277.1999.tb04083.x
Chick, J., Gough, K., Kershaw, P.,
Hore, B., Mehta, B., Ritson, B.,
et al. (1992). Disulfiram treatment
of alcoholism. Br. J. Psychiatry 161,
84–89. doi: 10.1192/bjp.161.1.84
Correa, M., Salamone, J. D., Segovia,
K. N., Pardo, M., Longoni, R.,
Spina, L., et al. (2012). Piecing
together the puzzle of acetaldehyde
as a neuroactive agent. Neurosci.
Biobehav. Rev, 36, 404–430. doi:
10.1016/j.neubiorev.2011.07.009
Crabbe, J. C., Phillips, T. J., Harris,
R. A., Arends, M. A., and Koob,
G. F. (2006). Alcohol-related
genes: contributions from studies
with genetically engineered mice.
Addiction Biol. 11, 195–269. doi:
10.1111/j.1369-1600.2006.00038.x
Daoust, M., Lhuintre, J. P., Moore,
N., Saligaut, C., Flipo, J. L., and
Boismare, F. (1987). Is initial
sensitivity to ethanol corre-
lated with alcohol preference
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 80 | 6
Israel et al. Gene modifications and alcohol effects
in alcohol-drinking and non-
drinking rats. Alcohol Alcohol. 22,
409–414.
Deitrich, R. (2011). Ethanol as a
Prodrug: brain metabolism of
ethanolmediates its reinforcing
effects – a commentary. Alcohol.
Clin. Exp. Res.35, 581–583. doi:
10.1111/j.1530-0277.2011.01454.x
Dominy, N. J., Ross, C. F., and Smith,
T. D. (2004). Evolution of the spe-
cial senses in primates: past, present,
and future. Anat. Rec. A Discov. Mol.
Cell. Evol. Biol. 281, 1078–1082. doi:
10.1002/ar.a.20112
Duddley, T. (2000). Evolutionary ori-
gins of human alcoholism in pri-
mate frugivory. Q. Rev. Biol. 75,
3–15. doi: 10.1086/393255
Elmer, G. I., Meish, R. A., Goldberg,
S. R., and George, F. R. (1990).
Ethanol self-administration in
long sleep and short sleep mice
indicates reinforcement is not
inversely related to neurosensitiv-
ity. J. Pharmacol. Exp. Ther. 254,
1054–1062.
Eriksson, C. J. (1977). Acetaldehyde
metabolism in vivo during ethanol
oxidation. Adv. Exp. Med. Biol. 85A,
319–341.
Escrig, M. A., Pardo, M., Aragon,
C. M., and Correa, M. (2012).
Anxiogenic and stress-inducing
effects of peripherally admin-
istered acetaldehyde in mice:
similarities with the disulfiram-
ethanol reaction. Pharmacol.
Biochem. Behav. 100, 404–412. doi:
10.1016/j.pbb.2011.10.002
Gill, K., Menez, J. F., Lucas, D., and
Deitrich, R. A. (1992). Enzymatic
production of acetaldehyde
from ethanol in rat brain tis-
sue. Alcohol. Clin. Exp. Res. 16,
910–915. doi: 10.1111/j.1530-
0277.1992.tb01892.x
Halliwell, B. (2006). Oxidative
stress and neurodegener-
ation: where are we now.
J. Neurochem. 97, 1634–1658. doi:
10.1111/j.1471-4159.2006.03907.x
Harada, S., Agarwal, D. P., Goedde,
H. W., Tagaki, S., and Ishikawa,
B. (1982). Possible protective role
against alcoholism for aldehyde
dehydrogenase isozyme deficiency
in Japan. Lancet 2, 827. doi:
10.1016/S0140-6736(82)92722-2
Harris, R. A., and Allan, A. M. (1985).
Functional coupling of gamma-
aminobutyric acid receptors to
chloride channels in brain mem-
branes. Science 228, 1108–1110. doi:
10.1126/science.2581319
Higuchi, S. (1994). Polymorphisms of
ethanol metabolizing enzyme genes
and alcoholism. Alcohol Alcohol.
Suppl 2, 29–34.
Hogarth, W. (1751). “Gin lane,” in
Hogarth’s Graphic Works, in Ronald
Paulson Yale University Press, 1965.
Huidobro-Toro, J. P., Bleck, V., Allan,
A. M., and Harris, R. A. (1987).
Neurochemical actions of anesthetic
drugs on the gamma-aminobutyric
acid receptor-chloride channel
complex. J. Pharmacol. Exp. Ther.
242, 963–969.
Jørgensen, C. H., Pedersen, B., and
Tønnesen, H. (2011). The efficacy
of disulfiram for the treatment
of alcohol use disorder. Alcohol.
Clin. Exp. Res. 35, 1749–1758. doi:
10.1111/j.1530-0277.2011.01523.x
Juricic, M. A., Berríos-Cárcamo, P.
A., Acevedo, M. L., Israel, Y.,
Almodóvar, I., Cassels, B. K. (2012).
Salsolinol and isosalsolinol: con-
densation products of acetaldehyde
and dopamine. Separation of their
enantiomers in the presence of a
large excess of dopamine. J. Pharm.
Biomed. Anal. 63, 170–174. doi:
10.1016/j.jpba.2012.02.002
Kaplitt, M. G., Feigin, A., Tang, C.,
Fitzsimons, H. L., Mattis, P., Lawlor,
P. A., et al. (2007). Safety and
tolerability of gene therapy with
an adeno-associated virus (AAV)
borne GAD gene for Parkinson’s
disease: an open label, phase I
trial. Lancet 369, 2097–2105. doi:
10.1016/S0140-6736(07)60982-9
Karahanian, E., Quintanilla, M. E.,
Tampier, L., Rivera-Meza, M.,
Bustamante, D., Gonzalez-Lira, V.,
et al. (2011). Ethanol as a Prodrug:
brain metabolism of etanol medi-
ates its reinforcing effects. Alcohol.
Clin. Exp. Res. 35, 606–612. doi:
10.1111/j.1530-0277.2011.01439.x
Khanna, J. M., and Israel, Y. (1980).
Ethanol metabolism. Int. Rev.
Physiol. 21, 275–315.
King, G. S., Goodwin, B. L., and
Sandler, M. (1974). Isosalsolinol
formation: a secondary reaction
in the Pictet-Spengler conden-
sation, J. Pharm. Pharmacol. 26,
476–478. doi: 10.1111/j.2042-
7158.1974.tb09323.x
Krasowski, M. D., Koltchine, V. V.,
Rick, C. E., Ye, Q., Finn, S. E., and
Harrison, N. L. (1998). Propofol
and other intravenous anesthetics
have sites of action on the gamma-
aminobutyric acid type A receptor
distinct from that for isoflurane.
Mol. Pharmacol. 53, 530–538.
Ledesma, J. C., and Aragon, C. M.
(2013). Acquisition and recon-
ditioning of ethanol-induced
conditioned place preference in
mice is blocked by the H2O2
scavenger alpha lipoic acid.
Psychopharmacology 226, 673–685.
doi: 10.1007/s00213-012-2831-9
Levitan, E. S., Schofield, P. R., Burt,
D. R., Rhee, L. M., Wisden, W.,
Köhler, M., et al. (1988). Structural
and functional basis for GABAA
receptor heterogeneity. Nature 335,
76–79. doi: 10.1038/335076a0
Lindros, K. O., and Hillbom, M.
E. (1979). Acetaldehyde in cere-
brospinal fluid: its near-absence in
ethanol-intoxicated alcoholics.Med.
Biol. 57, 246–247.
Lovinger, D. M., White, G., and
Wright, F. F. (1989). Ethanol
inhibits NMDA-activated ion
current in hippocampal neu-
rons. Science 243, 1721–1724. doi:
10.1126/science.2467382
Luczak, S. E., Glatt, S. J., and Wall,
T. L. (2006). Meta-analyses
of ALDH2 and ADH1B with
alcohol dependence in Asians.
Psychol. Bull. 132, 607–621. doi:
10.1037/0033-2909.132.4.607
Mezey, E. (1976). Ethanol metabolism
and ethanol-drug interactions.
Biochem. Pharmacol. 25, 869–875.
doi: 10.1016/0006-2952(76)90305-1
Mihic, S. J., McQuilkin, S. J., Eger, E.
I. 2nd, Ionescu, P., and Harris, R.
A. (1994). Potentiation of gamma-
aminobutyric acid type A receptor-
mediated chloride currents by novel
halogenated compounds correlates
with their abilities to induce gen-
eral anesthesia. Mol. Pharmacol. 46,
851–857.
Mihic, S. J., Ye, Q., Wick, M. J.,
Koltchine, V. V., Krasowski, M. D.,
Finn, S. E., et al. (1997). Sites
of alcohol and volatile anaesthetic
action on GABA(A) and glycine
receptors. Nature 389, 385–389. doi:
10.1038/38738
Mizoi, Y., Tatsuno, Y., Adachi, J.,
Kigame, M., Fukunaga, T., Hishida,
S., et al. (1983). Alcohol sen-
sitivity related to polymorphism
of alcohol-metabolizing enzymes
in Japanese. Pharmacol. Biochem.
Behav. 18(Suppl. 1), 127–133. doi:
10.1016/0091-3057(83)90159-4
Ocaranza, P., Quintanilla, M. E.,
Tampier, L., Karahanian, E.,
Sapag, A., and Israel, Y. (2008).
Gene therapy reduces ethanol
intake in an animal model of
alcohol dependence. Alcohol.
Clin. Exp. Res. 32, 52–57. doi:
10.1111/j.1530-0277.2007.00553.x
Ogata, J., Shiraishi, M., Namba, T.,
Smothers, C. T., Woodward, J. J.,
and Harris, R. A. (2006). Effects of
anesthetics on mutant N-methyl-
D-aspartate receptors expressed
in Xenopus oocytes. J. Pharmacol.
Exp. Ther. 318, 434–443. doi:
10.1124/jpet.106.101691
Oster, S. M., Toalston, J. E., Kuc, K.
A., Pommer, T. J., Murphy, J. M.,
Lumeng, L., et al. (2006). Effect
of multiple alcohol deprivations on
operant ethanol self-administration
by high-ethanol drinking replicate
rat lines. Alcohol 38, 155–164. doi:
10.1016/j.alcohol.2006.06.001
Peterson, D. R., and Tabakoff, B.
(1979). Characterization of
brain acetaldehyde oxidizing
systems in the mouse. Drug
Alcohol Depend. 4, 137–144. doi:
10.1016/0376-8716(79)90054-1
Pritchett, D. B., Lüddens, H., and
Seeburg, P. H. (1989). Type I
and type II GABAA-benzodiazepine
receptors produced in transfected
cells. Science 245, 1389–1392. doi:
10.1126/science.2551039
Quertemont, E., Tambour, S., and
Tirelli, E. (2005). The role of
acetaldehyde in the neurobehav-
ioral effects of ethanol: a compre-
hensive review of animal studies.
Prog. Neurobiol. 75, 247–274. doi:
10.1016/j.pneurobio.2005.03.003
Quintanilla, M. E., Israel, Y., Sapag, A.,
and Tampier, L. (2006). The UChA
and UChB rat lines: metabolic
and genetic differences influenc-
ing ethanol intake. Addiction Biol.
11, 310–323. doi: 10.1111/j.1369-
1600.2006.00030.x
Quintanilla, M. E., Tampier, L.,
Karahanian, E., Rivera-Meza,
M., Herrera-Marschitz, M., and
Israel, Y. (2012). Reward and
relapse: complete gene-induced
dissociation in an animal model
of alcohol dependence. Alcohol.
Clin. Exp. Res. 36, 517–522. doi:
10.1111/j.1530-0277.2011.01606.x
Quintanilla, M. E., Tampier, L., Sapag,
A., Gerdzen, Z., and Israel, Y.
(2007). Sex differences, alcohol
dehydrogenase, acetaldehyde burst,
and aversion to ethanol in the rat: a
systems perspective. Am. J. Physiol.
Endocrinol. Metab. 293, E531–E537.
doi: 10.1152/ajpendo.00187.2007
Quintanilla, M. E., Tampier, L., Valle-
Prieto, A., Sapag, A., and Israel,
Y. (2005a). Complex I regulates
mutant mitochondrial aldehyde
dehydrogenase activity and vol-
untary ethanol consumption in
rats. FASEB J. 19, 36–42. doi:
10.1096/fj.04-2172com
Quintanilla, M. E., Tampier, L.,
Sapag., and Israel, Y. (2005b).
Polymorphisms in the mitochon-
drial aldehyde dehydrogenase gene
(Aldh2) determine peak blood
acetaldehyde levels and voluntary
ethanol consumption in rats.
Pharmacogenet. Genomics 15,
427–431. doi: 10.1097/01213011-
200506000-00009
Ratcliff, W. C., Denison, R. F., Borrelo,
M., and Travisano, M. (2012).
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 80 | 7
Israel et al. Gene modifications and alcohol effects
Experimental evolution of mul-
ticellularity. Proc. Natl. Acad.
Sci. U.S.A. 109, 1595–1600. doi:
10.1073/pnas.1115323109
Rhee, S. G., Chae, H. Z., and Kim,
K. (2005). Peroxiredoxins: a his-
torical overview and speculative
preview of novel mechanisms
and emerging concepts in cell
signaling. Free Radic. Biol. Med.
38, 1543–1552. doi: 10.1016/
j.freeradbiomed.2005.02.026
Riley, E. P., Worsham, E. D., Lester,
D., and Freed, E. X. (1977).
Selective breeding of rats for
differences in reactivity to alco-
hol. An approach to an animal
model of alcoholism. II. Behavioral
measures. J. Stud. Alcohol 38,
1705–1717.
Rivera-Meza, M., Quintanilla, M. E.,
Tampier, L., Mura, C. V., Sapag, A.,
and Israel, Y. (2010). Mechanism
of protection against alcoholism
by an alcohol dehydrogenase
polymorphism: development of
an animal model. FASEB J. 24,
266–274. doi: 10.1096/fj.09-132563
Robbins, T. W., and Murphy, E. R.
(2006). Behavioural pharma-
cology: 40+ years of progress,
with a focus on glutamate
receptors and cognition. Trends
Pharmacol. Sci. 27, 141–148. doi:
10.1016/j.tips.2006.01.009
Rodd, Z. A., Bell, R. L., Kuc, K.
A., Murphy, J. M., Lumeng,
L., and McBride, W. J. (2008).
Effects of concurrent access to
multiple ethanol concentra-
tions and repeated deprivations
on alcohol intake of high-
alcohol-drinking (HAD) rats.
Addiction Biol. 14, 152–164. doi:
10.1111/j.1369-1600.2008.00140.x
Rodd, Z. A., Bell, R. L., Zhang,
Y., Murphy, J. M., Goldstain,
A., Zafarroni, A., et al. (2005).
Regional heterogeneity for the
intracranial self-administration
of ethanol and acetaldehyde
within the ventral tegmental area
of alcohol-preferring (P) rats:
involvement of dopamine and sero-
tonin. Neuropsychopharmacology
30, 330–338. doi: 10.1038/
sj.npp.1300561
Rodd-Henricks, Z. A., Bell, R. L., Kuc,
K. A., Murphy, J. M., McBride,
W. J., Lumeng, L., et al. (2001).
Effect of concurrent access to
multiple ethanol concentrations
and repeated deprivations on
alcohol intake of alcohol-preferring
rats. Alcohol. Clin. Exp. Res. 25,
1140–1150. doi: 10.1111/j.1530-
0277.2001.tb02328.x
Rotzinger, S., Smith, B. R., and Amit,
Z. (1994). Catalase inhibition atten-
uates the acquisition of ethanol and
saccharin-quinine consumption in
laboratory rats. Behav. Pharmacol.
5, 203–209. doi: 10.1097/00008877-
199404000-00012
Sapag, A., Tampier, L., Valle-Prieto, A.,
Quintanilla, M. E., Moncada, M. E.,
and Israel, Y. (2003). Mutations in
mitochondrial aldehyde dehydro-
genase (ALDH2) change cofactor
affinity and segregate with volun-
tary alcohol consumption in rats.
Pharmacogenetics 13, 509–515.
doi: 10.1097/00008571-200308000-
00009
Shimoda, T., Kohno, S., Takao, A.,
Fujiwara, C., Matsuse, H., Sakai,
H., et al. (1996). Investigation
of the mechanism of alcohol-
induced bronchial asthma. J. Allergy
Clin. Immuno. 97, 74–84. doi:
10.1016/S0091-6749(96)70285-3
Sinclair, J. D., and Li, T.-K. (1989).
Long and short alcohol depriva-
tion effects on AA and P alcohol-
preferring rats. Alcohol 6, 505–509.
doi: 10.1016/0741-8329(89)90059-1
Sinclair, J. D., and Senter, R. J. (1968).
Development of an alcohol-
deprivation effect in rats. Q. J. Stud.
Alcohol 29, 863–867.
Sinclair, J. D., and Senter, R. J. (1977).
Increased preference for ethanol in
rats following deprivation Psychon.
Sci. 8, 11–12.
Sinclair, J. D., Walker, S., and Jordan,
W. (1973). Behavioral and physio-
logical changes associated with var-
ious durations of alcohol depriva-
tion in rats. Q. J. Stud. Alcohol 34,
544–757.
Spanagel, R., and Hölter, S. M.
(1999). Long-term alcohol self-
administration with repeated
alcohol deprivation phases: an
animal model of alcoholism.
Alcohol Alcohol. 34, 231–243. doi:
10.1093/alcalc/34.2.231
Stowell, A., Hillbom, M., Salaspuro,
M., and Lindros, K. O. (1980).
Low acetaldehyde levels in blood,
breath and cerebrospinal fluid of
intoxicated humans as assayed by
improved methods. Adv. Exp. Med.
Biol. 132, 635–645.
Suzdak, P. D., Glowa, J. R., Crawley,
J. N., Schwartz, R. D., Skolnick,
P., and Paul, S. M. (1986). A
selective imidazobenzodiazepine
antagonist of ethanol in the rat.
Science 234, 1243–1247. doi:
10.1126/science.3022383
Tabakoff, B., Anderson, R, A., and
Ritzmann, R. F. (1976). Brain
acetaldehyde after ethanol
administration. Biochem.
Pharmacol. 25, 1305–1309. doi:
10.1016/0006-2952(76)90094-0
Tampier, L., and Mardones, J. (1979).
Catalase mediated oxidation of
ethanol by rat brain homogenates.
IRCS Med. Sci. 7, 389.
Tampier, L., Quintanilla, M. E.,
Karahanian, E., Rivera-Meza, M.,
Herrera-Marschitz, M., and Israel,
Y. (2013). The alcohol depriva-
tion effect:marked inhibition by
anticatalase gene administration
into the ventral tegmental area in
rats Alcohol Clin. Exp. Res. doi:
10.1111/acer.12101. [Epub ahead of
print].
Tampier, L., Quintanilla, M. E., and
Mardones, J. (1995). Effects of
aminotriazole on ethanol, water,
and food intake and on brain
catalase in UChA and UChB
rats. Alcohol 12, 341–344. doi:
10.1016/0741-8329(95)00014-I
Thomasson, H. R., Edenberg, H. J.,
Crabb, D. W., Mai, X. L., Jerome,
R. E., Li, T. K., et al. (1991).
Alcohol and aldehyde dehydroge-
nase genotypes and alcoholism in
Chinese men. Am. J. Hum. Genet.
48, 677–681.
Tu, G. C., and Israel, Y. (1995). Alcohol
consumption by Orientals in North
America is predicted largely by a
single gene. Behav. Genet. 25, 59–65.
doi: 10.1007/BF02197242
Turrens, J. F. (2003). Mitochondrial
formation of reactive oxygen
species. J. Physiol. 552, 335–344.
doi: 10.1113/jphysiol.2003.049478
Vengeliene, V., Celerier, E., Chaskiel,
L., Penzo, F., and Spanagel,
R. (2009). Compulsive alco-
hol drinking in rodents.
Addiction Biol. 14, 384–396. doi:
10.1111/j.1369-1600.2009.00177.x
Weight, F. F., Aguayo, L. G., White, G.,
Lovinger, D. M., and Peoples, R. W.
(1992). GABA- and glutamate-gated
ion channels as molecular sites
of alcohol and anesthetic action.
Adv. Biochem. Psychopharmacol. 47,
335–347.
Wirkner, K., Poelchen, W., Köles, L.,
Múlberg, K., Scheibler, P., Allgaier,
C., et al. (1999). Ethanol-induced
inhibition of NMDA receptor chan-
nels. Neurochem. Int. 35, 153–162.
doi: 10.1016/S0197-0186(99)
00057-1
Wright, J. M., Peoples, R. W., and
Weight, F. F. (1996). Single-channel
and whole-cell analysis of ethanol
inhibition of NMDA-activated cur-
rents in cultured mouse cortical and
hippocampal neurons. Brain Res.
738, 249–256. doi: 10.1016/S0006-
8993(96)00780-9
Zimatkin, S. M., and Buben, A.
L. (2007). Ethanol oxidation
in the living brain. Alcohol
Alcohol. 42, 529–532. doi:
10.1093/alcalc/agm059
Zimatkin, S. M., Pronko, S. P.,
Vasiliou, V., Gonzalez, F. J., and
Deitrich, R. A. (2006).Enzymatic
mechanisms of ethanol oxida-
tion in the brain. Alcohol. Clin.
Exp. Res. 30, 1500–1505. doi:
10.1111/j.1530-0277.2006.00181.x
Zintzaras, E., Stefanidis, I., Santos,
M., and Vidal, F. (2006). Do
alcohol-metabolizing enzyme
gene polymorphisms increase
the risk of alcoholism and alco-
holic liver disease? Hepatology
43, 352–361. doi: 10.1002/
hep.21023
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 06 May 2013; accepted: 18 June
2013; published online: 08 July 2013.
Citation: Israel Y, Rivera-Meza M,
Karahanian E, Quintanilla ME, Tampier
L, Morales P and Herrera-Marschitz
M (2013) Gene specific modifications
unravel ethanol and acetaldehyde
actions. Front. Behav. Neurosci. 7:80.
doi: 10.3389/fnbeh.2013.00080
Copyright © 2013 Israel, Rivera-Meza,
Karahanian, Quintanilla, Tampier,
Morales and Herrera-Marschitz.
This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and repro-
duction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 80 | 8
